<p>, /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) 今天宣佈，2025 年 12 月 16 日，公司批准了非法定股票期權，購買總計 3,825 股普通股和 4,385 個限制性股票單位（&#34;RSUs&#34;），每個單位代表在歸屬時獲得一股普通股的權利，授予五名新員工。這些獎勵是根據納斯達克誘導授予例外條款作為新員工薪酬的一部分。</p>
<p><img src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/2582388/PTC_LOGO_Logo_Logo.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/2582388/PTC_LOGO_Logo_Logo.jpg"/></p>
<p>這些誘導授予於 2025 年 12 月 16 日獲得 PTC 薪酬委員會的批准，並作為每位員工接受公司僱傭的誘導材料，根據納斯達克上市規則 5635(c)(4) 進行。</p>
<p>所有股票期權的行使價格為每股 75.42 美元，這是 2025 年 12 月 16 日 PTC 普通股的收盤價。股票期權的有效期為 10 年，並在四年內歸屬，適用員工的新僱傭日期的第一週年時，原始股份數量的 25% 歸屬，之後每個三個月期末歸屬原始股份數量的 6.25%，直到完全歸屬，前提是員工在適用的歸屬日期繼續為公司服務。RSUs 將在四年內歸屬，適用員工的新僱傭日期的每個週年時，原始股份數量的 25% 歸屬，直到完全歸屬，前提是員工在適用的歸屬日期繼續為公司服務。</p>
<p><strong>關於 PTC Therapeutics, Inc.</strong> PTC 是一家全球生物製藥公司，致力於為生活在罕見疾病中的兒童和成人發現、開發和商業化臨牀差異化藥物。PTC 正在推進一條強大而多樣化的變革性藥物管線，作為其使命的一部分，旨在為有未滿足醫療需求的患者提供最佳治療方案。公司的戰略是利用其科學專業知識和全球商業基礎設施，為患者和其他利益相關者優化價值。要了解更多關於 PTC 的信息，請訪問 www.ptcbio.com，並在 LinkedIn、X、Facebook 和 Instagram 上關注我們。</p>
<p><strong>如需更多信息，請聯繫：</strong></p>
<p><strong>投資者：</strong> Ellen Cavaleri</p>
<p>+1 (615) 618-8228</p>
<p>ecavaleri@ptcbio.com</p>
<p><strong>媒體：</strong> Jeanine Clemente</p>
<p>+1 (908) 912-9406</p>
<p>jclemente@ptcbio.com</p>
<p>來源 PTC Therapeutics, Inc.</p>

PTCT

<p>PTC Therapeutics 宣佈根據納斯達克上市規則 5635(c)(4) 向五名新員工授予誘導性補償。該補償包括 3,825 股的非法定股票期權和 4,385 個限制性股票單位（RSUs）。股票期權的有效期為 10 年，分四年歸屬，行使價格為每股 75.42 美元。RSUs 也在四年內歸屬。這些補償是新員工薪酬的一部分</p>

<p>, /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Dec. 16, 2025, the company approved non-statutory stock options to purchase an aggregate of 3,825 shares of its common stock and 4,385 restricted stock units (&#34;RSUs&#34;), each representing the right to receive one share of its common stock upon vesting, to five new employees. The awards were made pursuant to the Nasdaq inducement grant exception as a component of the new hires' employment compensation.</p>
<div class="lb-trans"><p>, /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) 今天宣佈，2025 年 12 月 16 日，公司批准了非法定股票期權，購買總計 3,825 股普通股和 4,385 個限制性股票單位（&#34;RSUs&#34;），每個單位代表在歸屬時獲得一股普通股的權利，授予五名新員工。這些獎勵是根據納斯達克誘導授予例外條款作為新員工薪酬的一部分。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/2582388/PTC_LOGO_Logo_Logo.jpg" alt="" original-src="https://mma.prnewswire.com/media/2582388/PTC_LOGO_Logo_Logo.jpg"/></p>
<p>The inducement grants were approved by PTC's Compensation Committee on Dec. 16, 2025, and are being made as an inducement material to each employee's acceptance of employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4).</p>
<div class="lb-trans"><p>這些誘導授予於 2025 年 12 月 16 日獲得 PTC 薪酬委員會的批准，並作為每位員工接受公司僱傭的誘導材料，根據納斯達克上市規則 5635(c)(4) 進行。</p>
</div><p>All stock option awards have an exercise price of $75.42 per share, the closing price of PTC's common stock on Dec. 16, 2025, the date of the grant. The stock options each have a 10-year term and vest over four years, with 25% of the original number of shares vesting on the first anniversary of the applicable employee's new hire date and 6.25% of the original number of shares vesting at the end of each subsequent three-month period thereafter until fully vested, subject to the employee's continued service with the company through the applicable vesting dates. The RSUs each will vest over four years, with 25% of the original number of shares vesting on each annual anniversary of the applicable employee's new hire date until fully vested, subject to the employee's continued service with the company through the applicable vesting dates.</p>
<div class="lb-trans"><p>所有股票期權的行使價格為每股 75.42 美元，這是 2025 年 12 月 16 日 PTC 普通股的收盤價。股票期權的有效期為 10 年，並在四年內歸屬，適用員工的新僱傭日期的第一週年時，原始股份數量的 25% 歸屬，之後每個三個月期末歸屬原始股份數量的 6.25%，直到完全歸屬，前提是員工在適用的歸屬日期繼續為公司服務。RSUs 將在四年內歸屬，適用員工的新僱傭日期的每個週年時，原始股份數量的 25% 歸屬，直到完全歸屬，前提是員工在適用的歸屬日期繼續為公司服務。</p>
</div><p><strong>About PTC Therapeutics, Inc.</strong> PTC is a global biopharmaceutical company dedicated to the discovery, development, and commercialization of clinically differentiated medicines for children and adults living with rare disorders. PTC is advancing a robust and diversified pipeline of transformative medicines as part of its mission to provide access to best-in-class treatments for patients with unmet medical needs. The company's strategy is to leverage its scientific expertise and global commercial infrastructure to optimize value for patients and other stakeholders. To learn more about PTC, please visit www.ptcbio.com and follow us on LinkedIn, X, Facebook, and Instagram.</p>
<div class="lb-trans"><p><strong>關於 PTC Therapeutics, Inc.</strong> PTC 是一家全球生物製藥公司，致力於為生活在罕見疾病中的兒童和成人發現、開發和商業化臨牀差異化藥物。PTC 正在推進一條強大而多樣化的變革性藥物管線，作為其使命的一部分，旨在為有未滿足醫療需求的患者提供最佳治療方案。公司的戰略是利用其科學專業知識和全球商業基礎設施，為患者和其他利益相關者優化價值。要了解更多關於 PTC 的信息，請訪問 www.ptcbio.com，並在 LinkedIn、X、Facebook 和 Instagram 上關注我們。</p>
</div><p><strong>For more information, please contact:</strong></p>
<div class="lb-trans"><p><strong>如需更多信息，請聯繫：</strong></p>
</div><p><strong>Investors:</strong> Ellen Cavaleri</p>
<div class="lb-trans"><p><strong>投資者：</strong> Ellen Cavaleri</p>
</div><p>+1 (615) 618-8228</p>
<div class="lb-trans"><p>+1 (615) 618-8228</p>
</div><p>ecavaleri@ptcbio.com</p>
<div class="lb-trans"><p>ecavaleri@ptcbio.com</p>
</div><p><strong>Media:</strong> Jeanine Clemente</p>
<div class="lb-trans"><p><strong>媒體：</strong> Jeanine Clemente</p>
</div><p>+1 (908) 912-9406</p>
<div class="lb-trans"><p>+1 (908) 912-9406</p>
</div><p>jclemente@ptcbio.com</p>
<div class="lb-trans"><p>jclemente@ptcbio.com</p>
</div><p>SOURCE PTC Therapeutics, Inc.</p>
<div class="lb-trans"><p>來源 PTC Therapeutics, Inc.</p>
</div>

PTC Therapeutics 根據納斯達克上市規則 5635(c)(4) 報告了誘導性授予 | PTCT 股票新聞